Darryl P Leong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3338043/publications.pdf

Version: 2024-02-01

91712 147566 9,281 77 31 69 citations h-index g-index papers 77 77 77 15483 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 462-473.	1.4	8
2	The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 253-262.	1.4	21
3	Characterizing Frailty In Myeloproliferative Neoplasms: results from the ORCHID study. Leukemia Research, 2022, 113, 106788.	0.4	O
4	Variations in the financial impact of the COVID-19 pandemic across 5 continents: A cross-sectional, individual level analysis. EClinicalMedicine, 2022, 44, 101284.	3.2	21
5	Medications for blood pressure, blood glucose, lipids, and anti-thrombotic medications: relationship with cardiovascular disease and death in adults from 21 high-, middle-, and low-income countries with an elevated body mass index. European Journal of Preventive Cardiology, 2022, 29, 1817-1826.	0.8	2
6	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 786-795.	1.4	6
7	Variations in the association of height with mortality, cardiovascular disease and cancer in low-, middle- and high-income countries. International Journal of Epidemiology, 2022, 51, 1304-1316.	0.9	3
8	The Cardiologist's Role in the Management of Patients with a Genitourinary Cancer Israel Medical Association Journal, 2022, 24, 175-178.	0.1	0
9	Clinical Practice Guidelines in Cardio-Oncology. Heart Failure Clinics, 2022, 18, 489-501.	1.0	12
10	In nonischemic systolic HF, prophylactic ICDs did not reduce all-cause mortality vs. usual care at 10 y. Annals of Internal Medicine, 2022, 175, JC66.	2.0	0
11	The Indirect Consequences of the Response to the COVID-19 Pandemic. Journal of the American College of Cardiology, 2021, 77, 186-188.	1.2	3
12	The prediction of Metabolic Syndrome alterations is improved by combining waist circumference and handgrip strength measurements compared to either alone. Cardiovascular Diabetology, 2021, 20, 68.	2.7	19
13	Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. Heart, 2021, 107, 1130-1137.	1.2	6
14	Response to †Adverse cardiac outcomes in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors'. Heart, 2021, 107, 1680.2-1681.	1.2	0
15	COVID-19 Vaccination Prioritization on the Basis of Cardiovascular Risk Factors and Number Needed to Vaccinate to Prevent Death. Canadian Journal of Cardiology, 2021, 37, 1112-1116.	0.8	14
16	Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study. Journal of Clinical Oncology, 2021, 39, 3453-3462.	0.8	32
17	Development and Comparability of a Short Food-Frequency Questionnaire to Assess Diet in Prostate Cancer Patients: The Role of Androgen Deprivation Therapy in CArdiovascular Disease – A Longitudinal Prostate Cancer Study (RADICAL PC) Substudy. Current Developments in Nutrition, 2021, 5, nzab106.	0.1	2
18	Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation. Current Oncology Reports, 2021, 23, 113.	1.8	22

#	Article	IF	Citations
19	Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. Circulation, 2021, 144, 1295-1307.	1.6	7 5
20	ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis. Lung Cancer, 2021, 161, 9-17.	0.9	16
21	Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease. Heart, 2021, 107, 667-673.	1.2	13
22	Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet, The, 2020, 395, 785-794.	6.3	428
23	Modifiable risk factors, cardiovascular disease, and mortality in 155â€^722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet, The, 2020, 395, 795-808.	6.3	935
24	The association of grip strength with cardiovascular diseases and all-cause mortality in people with hypertension: Findings from the Prospective Urban Rural Epidemiology China Study. Journal of Sport and Health Science, 2020, 10, 629-629.	3.3	15
25	Is It Only Takotsubo Syndrome? Cardiac MRI and a Case of Delayed ST-Elevation. CJC Open, 2020, 2, 722-725.	0.7	0
26	A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry. American Heart Journal, 2020, 227, 56-63.	1.2	24
27	Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study. Journal of Urology, 2020, 203, 1109-1116.	0.2	49
28	The Evolution of β-Blockers in CoronaryÂArteryÂDiseaseÂand HeartÂFailureÂ(Part 1/5). Journal of the American College of Cardiology, 2019, 74, 672-682.	1.2	44
29	From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and HeartÂFailure (Part 2/5). Journal of the American College of Cardiology, 2019, 74, 683-698.	1.2	22
30	Safety of Continuing Trastuzumab DespiteÂMildÂCardiotoxicity. JACC: CardioOncology, 2019, 1, 1-10.	1.7	45
31	Major Bleeding in Patients With CoronaryÂor Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. Journal of the American College of Cardiology, 2019, 74, 1519-1528.	1.2	30
32	Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study. The Lancet Global Health, 2019, 7, e613-e623.	2.9	122
33	Are the cardiac effects of alcohol good, bad, or neither?. European Heart Journal, 2019, 40, 712-714.	1.0	3
34	Reversible Cabozantinib-Induced Cardiomyopathy. Canadian Journal of Cardiology, 2019, 35, 544.e1-544.e2.	0.8	9
35	Adjuvant Trastuzumab Therapy: Can We Balance Efficacy and Safety?. Oncologist, 2019, 24, 1405-1409.	1.9	2
36	Depression and prostate cancer: A focused review for the clinician. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 282-288.	0.8	62

#	Article	IF	CITATIONS
37	Antiplatelet use in patients with essential thrombocythemia: A survey of opinion and Canadian practice. Thrombosis Research, 2018, 167, 6-8.	0.8	1
38	Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area. Canadian Journal of Cardiology, 2018, 34, 1059-1068.	0.8	95
39	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 219-229.	6.3	651
40	A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. Blood Advances, 2018, 2, 1935-1945.	2.5	34
41	Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 2018, 13, e0209486.	1.1	49
42	Thiamine versus placebo in older heart failure patients: study protocol for a randomized controlled crossover feasibility trial (THIAMINE-HF). Pilot and Feasibility Studies, 2018, 4, 149.	0.5	6
43	Adiposity and mortality in South Asians: challenges to the existing paradigm. The Lancet Global Health, 2018, 6, e712-e713.	2.9	1
44	Varying Effects of Body Mass Index and Mortality in Different Risk Groups. American Journal of Cardiology, 2018, 122, 1155-1160.	0.7	9
45	Alcohol and Cardiovascular Disease: How Much is Too Much?. Current Atherosclerosis Reports, 2017, 19, 13.	2.0	45
46	Imaging Asymptomatic Individuals forÂCoronary Disease â^—. JACC: Cardiovascular Imaging, 2017, 10, 318-320.	2.3	0
47	Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial. Canadian Journal of Cardiology, 2017, 33, 1027-1035.	0.8	133
48	AN UNSUSPECTED CASE OF MYOCARDITIS ASSOCIATED WITH NIVOLUMAB USE. Journal of the American College of Cardiology, 2017, 69, 2364.	1.2	1
49	The effect of physical activity on mortality and cardiovascular disease in 130â€^000 people from 17 high-income, middle-income, and low-income countries: the PURE study. Lancet, The, 2017, 390, 2643-2654.	6.3	838
50	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 1319-1330.	13.9	1,745
51	Reducing the Global Burden of Cardiovascular Disease, Part 1. Circulation Research, 2017, 121, 677-694.	2.0	639
52	Reducing the Global Burden of Cardiovascular Disease, Part 2. Circulation Research, 2017, 121, 695-710.	2.0	256
53	Subclinical Atrial Fibrillation in Older Patients. Circulation, 2017, 136, 1276-1283.	1.6	194
54	Left Atrial Dysfunction in the Pathogenesis of Cryptogenic Stroke: Novel Insights from Speckle-Tracking Echocardiography. Journal of the American Society of Echocardiography, 2017, 30, 71-79.e1.	1.2	60

#	Article	IF	CITATIONS
55	Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Advances, 2017, 1, 772-778.	2.5	82
56	Population Muscle Strength Predicts Olympic Medal Tallies: Evidence from 20 Countries in the PURE Prospective Cohort Study. PLoS ONE, 2017, 12, e0169821.	1.1	6
57	The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood, 2016, 128, 138-140.	0.6	190
58	Reference ranges of handgrip strength from 125,462 healthy adults in 21 countries: a prospective urban rural epidemiologic (PURE) study. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 535-546.	2.9	191
59	Health system barriers and facilitators to medication adherence for the secondary prevention of cardiovascular disease: a systematic review. Open Heart, 2016, 3, e000438.	0.9	36
60	Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?. Therapeutic Advances in Urology, 2016, 8, 118-129.	0.9	52
61	Factors Associated with Low Flow in Aortic Valve Stenosis. Journal of the American Society of Echocardiography, 2016, 29, 158-165.	1.2	23
62	Diagnostic Performance of Transluminal Attenuation Gradient and Noninvasive Fractional Flow Reserve Derived from 320–Detector Row CT Angiography to Diagnose Hemodynamically Significant Coronary Stenosis: An NXT Substudy. Radiology, 2016, 279, 75-83.	3.6	48
63	The Relationship between Time from Myocardial Infarction, Left Ventricular Dyssynchrony, and the Risk for Ventricular Arrhythmia: Speckle-Tracking Echocardiographic Analysis. Journal of the American Society of Echocardiography, 2015, 28, 470-477.	1.2	38
64	Impact of weight reduction on pericardial adipose tissue and cardiac structure in patients with atrial fibrillation. American Heart Journal, 2015, 169, 655-662.e2.	1.2	36
65	The ASLA Score: A CT Angiographic Index to Predict Functionally Significant Coronary Stenoses in Lesions with Intermediate Severity—Diagnostic Accuracy. Radiology, 2015, 276, 91-101.	3.6	17
66	Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet, The, 2015, 386, 266-273.	6.3	1,295
67	A novel coronary angiography index (DILEMMA score) for prediction of functionally significant coronary artery stenoses assessed by fractional flow reserve: A novel coronary angiography index. American Heart Journal, 2015, 169, 564-571.e4.	1.2	19
68	Alcohol consumption and cardiovascular disease, cancer, injury, admission to hospital, and mortality: a prospective cohort study. Lancet, The, 2015, 386, 1945-1954.	6.3	163
69	Predicting cardiovascular disease from handgrip strength: the potential clinical implications. Expert Review of Cardiovascular Therapy, 2015, 13, 1277-1279.	0.6	17
70	Utility of CMR Markers of Myocardial Injury in Predicting LV Functional Recovery: Results from PROTECTION AMI CMR Sub-study. Heart Lung and Circulation, 2015, 24, 891-897.	0.2	7
71	Republished: The evolving role of multimodality imaging in valvular heart disease. Postgraduate Medical Journal, 2014, 90, 317-327.	0.9	0
72	Left atrial volume and function in patients with atrial fibrillation. Current Opinion in Cardiology, 2014, 29, 437-444.	0.8	12

#	Article	IF	CITATIONS
73	Comparison of Diagnostic Accuracy of Combined Assessment Using Adenosine Stress Computed Tomography PerfusionÂ+ Computed Tomography Angiography With Transluminal Attenuation GradientÂ+ Computed Tomography Angiography Against Invasive Fractional Flow Reserve. Journal of the American College of Cardiology, 2014, 63, 1904-1912.	1.2	72
74	Patterns of Alcohol Consumption and Myocardial Infarction Risk. Circulation, 2014, 130, 390-398.	1.6	117
75	The Evolving Role of Cardiac Imaging in Percutaneous Valvular Intervention. Heart Lung and Circulation, 2013, 22, 704-716.	0.2	0
76	Speckle-tracking strain of the left atrium: a transoesophageal echocardiographic validation study. European Heart Journal Cardiovascular Imaging, 2013, 14, 898-905.	0.5	21
77	Imaging for Atrial Fibrillation. Current Problems in Cardiology, 2012, 37, 7-33.	1.1	17